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JOURNAL OF CLINICAL ONCOLOGY C O R R E S P O N D E N C E
Reply to M. Lambertini et al
Lambertini et al1 challenge the conclusion of the randomized
controlled study by Demeestere et al,2 which showed lack of go-
nadal protective effect from gonadotropin-releasing hormone
agonist (GnRHa) suppression in women with lymphoma based on
quantiﬁable serum ovarian reserve markers. Lambertini et al1
suggest that their studies3,4 have provided consistent results and
support conclusions opposite of those of Demeestere et al.2
However, the studies differ signiﬁcantly in their design, primary
outcome measures, patient populations, and pregnancy outcomes
(Table 1).5-7
Lambertini et al1 cite their own meta-analysis as proof of
GnRHa’s effectiveness for fertility preservation. As previously
discussed,5 meta-analyses do not correct for original study
weaknesses, and there is no biologic rationale in limiting meta-
analyses to breast cancer. When all studies that also include he-
matologic cancers are meta-analyzed, there remains no beneﬁt
from GnRHa.8
In addition to using a speciﬁc deﬁnition of premature ovarian
failure (POF) and primary ovarian insufﬁciency (POI) involving
amenorrhea and follicle-stimulating hormone greater than
40 mIU/mL as the primary outcome measure, Demeestere et al2
measured serum anti-mu¨llerian hormone (AMH) levels to cor-
roborate their ﬁndings. Serum AMH is the most reliable quanti-
tative marker in measuring ovarian reserve, diagnosing occult POI
(a state that is induced in most women by breast cancer che-
motherapy), and predicting age at menopause. None of the studies
that used AMH as a marker showed beneﬁt from the addition of
GnRHa treatment (Table 1).
Lambertini et al1 surmise that pregnancies nullify the des-
ignation of the study patients as having POI/POF. This is not
a correct assessment. First, there is 5% to 15% spontaneous live
birth rate among those who are designated to be in POI. Second,
spontaneous pregnancies do occur, even among those who are
induced to become menopausal by highly gonadotoxic pre-
conditioning chemotherapy for hematopoietic stem-cell trans-
plantation. Because in these young patients the egg quality is not
reduced after chemotherapy, the conceptions may be a result of the
ability of few remaining follicles to ovulate sporadically or possibly
the ability of some oocytes to self-repair chemotherapy-induced
DNA damage.5,9 Hence, pregnancy and POF/POI are not exclusive;
what is important is that the probability of pregnancy is signiﬁ-
cantly reduced after gonadotoxic chemotherapy.
Because breast cancer chemotherapy regimens often do not
induce complete POF/POI but rather result in occult POI, many
women still retain some reserve and have the ability to sponta-
neously conceive, albeit at reduced probability. Hence, it is not
surprising that, in an unblinded and non–placebo-controlled
design where the data are not corrected for pregnancy intent
and attempt and the women who are aware of their GnRHa
treatment could be moremotivated to attempt pregnancy, one may
inaccurately interpret those incidental conceptions as being
GnRHa-treatment enabled.
Lambertini et al1 also suggest that the use of norethisterone
by Demeestere et al2 blunted GnRHa’s beneﬁt on ovarian
function by suppressing the pituitary gonadotropin secretion in
the control group. This claim has numerous weaknesses. First,
primordial follicles that make up the ovarian reserve are qui-
escent, do not express gonadotropin or GnRHa receptors,5 and
hence have no pathway for responding to changes in serum
gonadotropin on gonadotropin-releasing hormone levels. Sec-
ond, if the authors’ claim were to be true, we would then expect
any form of ovarian suppression including oral contraceptives
to preserve ovarian function against chemotherapy, which is not
the case. Third, unlike combined contraceptive pills, progestin-
only treatments have a weak suppressive effect on serum go-
nadotropin levels. They induce amenorrhea primarily by their
effects on endometrium, not the pituitary. Fourth, to further cast
doubt that GnRHas preserve ovarian function by suppressing
serum follicle-stimulating hormone levels, a time-honored ran-
domized study by Waxman et al10 showed that serum gonado-
tropin levels are not suppressed below minimum physiologic levels
seen during a menstrual cycle (excluding the time of ovulation)
even after months of administration. Finally, Lambertini et al1
suggest that GnRHas may preserve ovarian endocrine function
even if they do not improve the chance of pregnancy. This hy-
pothesis does not par with ovarian biology. Hormone production
and fertility are coupled functions of the ovary. Hence, in studies
that show continued vaginal bleeding but not preservation of
fertility,3,4 one will have to look at explanations other than the
effectiveness of GnRHa treatment. These include observational
biases as a result of lack of blinding and placebo and use of
nonquantitative and subjective markers such as the return of any
kind of menstrual bleeding.5-7,11
On the basis of reliable data and basic ovarian biologic facts,
GnRHa suppression cannot be considered as an effectivemethod of
ovarian or fertility preservation. Just-in-case administration of
GnRHas over prolonged periods of time cannot be justiﬁed
given the cost, potential adverse effects including irreversible
bone loss, and the risk of counseling away from proven methods
of fertility preservation via embryo, oocyte, and ovarian tissue
cryopreservation.11
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Table 1. Comparison of Randomized Studies That Used Serum AMH to Studies by Lambertini et al3 and Moore et al4
Study Cancer Type
Patient Age
(years) Sample Size Primary Outcome Secondary Outcome Conclusion Limitations
Demeestre
et al,8a 2013
Hodgkin and
non-Hodgkin
lymphoma
18-38 GnRHa plus Chemo
plus norethisterone
acetate, n 5 65;
Chemo plus
norethisterone,
n 5 64
POF (FSH level
. 40 mIU/mL) at
12 months of
follow-up
AMH; early menstrual
FSH and E2
Triptorelin was not
associated with
a signiﬁcantly
decreased risk of
POF
Relatively short
follow-up period
Demeestre
et al,2 2016
Hodgkin and
non-Hodgkin
lymphoma
18-38 GnRHa plus Chemo,
n 5 32; Chemo
alone, n 5 35
POF (FSH level
. 40 mIU/mL) at
approximately
66 months of
follow-up
AMH; early menstrual
FSH and E2;
pregnancy rate
Triptorelin was not
associated with
a signiﬁcantly
decreased risk of
POF and did not
inﬂuence future
pregnancy rate
One of the best-
designed studies
Elgindy et al,8
2013
Breast cancer
(ER negative)
18-40 Early Chemo alone,
n 5 25; early
Chemo and
antagonist and
agonist, n 5 25;
delayed Chemo
alone, n 5 25;
delayed Chemo
plus GnRHa, n5 25
Resumption of
menses 12 months
after Chemo
Resumption of
regular menses;
random FSH, LH,
and E2, as well as
AFC and AMH,
12 months after
the end of Chemo
Triptorelin
cotreatment does
not
offer a signiﬁcant
protective effect on
ovarian function
One of the best-
designed studies
Gerber B
(ZORO
study),8b
2011
Breast cancer
(ER negative)
18-45 Chemo plus
goserelin, n 5 30;
Chemo alone,
n 5 31
Resumption of
menses
(2 consecutive
menstrual periods
within 21-35 days
in a time frame of
6 months after
Chemo) after
24-month follow-up
Time until recovery of
regular menses;
randomAFC, AMH,
FSH, LH, and E2 at
6, 12, 18, and 24
months after end of
Chemo; pregnancy
rate
Patients using
goserelin along
with Chemo did not
experience
a statistically
signiﬁcantly lower
risk of amenorrhea
6 months after
Chemo compared
with patients
receiving Chemo
alone
Serum FSH and E2
were not drawn on
cycle day 2 or 3, but
a less cycle
day–dependent
marker, AMH, was
used
Moore et al,4
2015
Breast cancer
(ER negative)
18-49 Chemo alone, n5 69;
Chemo plus
goserelin, n 5 66
Rate of POF (ovarian
failure was deﬁned
as amenorrhea
for the preceding
6 months and FSH
levels in the
postmenopausal
range at 2 years)
Pregnancy within the
past 5 years,
assessed annually;
ovarian dysfunction
(amenorrhea in
the preceding
3months) and FSH,
E2, or inhibin B
levels in the
postmenopausal
range
Administration of
goserelin with
Chemo appeared
to protect against
ovarian failure
Trial was terminated
prematurely as
a result of lack of
funding; any
bleeding without
regularity was
considered as
menstruation;
random hormone
proﬁle
measurements
without using
AMH; pregnancy
rates are not
different when
intent is considered
Lambertini
et al,3 2015)
Breast cancer
(ER negative
and positive)
24-45 Chemo alone,
n 5 133; GnRHa
plus Chemo,
n 5 148
Early menopause,
resumption of
menses (evaluated
by yearly
assessment of
menstrual activity)
Long-term ovarian
function
(considered as
preserved by the
occurrence of at
least 1 menstrual
cycle), pregnancies,
and disease-free
survival
Triptorelin was
associated with
higher long-term
probability of
ovarian function
recovery, without
a statistically
signiﬁcant
difference in
pregnancy rates
Any bleeding without
regularity was
considered as
menstruation; no
information regarding
the deﬁnition of
postmenopausal
status; no difference
was found in terms
of pregnancy
outcomes among
groups
Abbreviations: AFC, antral follicle count; AMH, anti-mu¨llerian hormone; Chemo, chemotherapy; E2, estradiol; ER, estrogen receptor; FSH, follicle-stimulating hormone;
GnRHa, gonadotropin-releasing hormone agonist; LH, luteinizing hormone; POF, premature ovarian failure; ZORO, Zoladex Rescue of Ovarian Function.
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